EP0888302A1 - N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene - Google Patents

N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene

Info

Publication number
EP0888302A1
EP0888302A1 EP97907277A EP97907277A EP0888302A1 EP 0888302 A1 EP0888302 A1 EP 0888302A1 EP 97907277 A EP97907277 A EP 97907277A EP 97907277 A EP97907277 A EP 97907277A EP 0888302 A1 EP0888302 A1 EP 0888302A1
Authority
EP
European Patent Office
Prior art keywords
compound
salt
formula
acid
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97907277A
Other languages
German (de)
English (en)
Inventor
Mitsuru Ohkubo
Fumie Takahashi
Toshio Yamanaka
Masayuki Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ZA962033A external-priority patent/ZA962033B/xx
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP0888302A1 publication Critical patent/EP0888302A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates to ⁇ -alanme derivative. More particularly, it relates to ⁇ -alanme derivative which is glycoprotem Ilb/IIIa antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibnnogen to blood platelets.
  • the present invention relates to ⁇ -alanme derivative. More particularly, it relates to ⁇ -alanme derivative which is glycoprotem Ilb/IIIa antagonist and inhibitor of platelet aggregation, and useful as : a drug for the prevention and/or the treatment of diseases caused by thrombus formation such as arterial thrombosis; arterial sclerosis; ischemic heart diseases [e.g. angina pectoris (e.g. stable angina pectoris, unstable angina pectoris including imminent infarction, etc.), myocardial infarction (e.g. acute myocardial infarction, etc.), coronary thrombosis, etc.] ; ischemic brain diseases [e.g. cerebral infarction ⁇ e.g.
  • cereoral thrombosis e.g. acute cerebral thrombosis, etc.
  • cerebral embolism etc. ⁇
  • transient cerebral ischemia e.g. transient ischemic attack, etc.
  • cerebrovascular spasm after cerebral hemorrhage e.g. cerebrovascular spasm after subarachnoid hemorrhage, etc.
  • pulmonary vascular diseases e.g. pulmonary thrombosis, pulmonary embolism etc.
  • peripheral circulatory disorder e.g. arteriosclerosis obliterans, thromboangiitis obliterans (i.e. Burger's disease), Raynaud's disease, complication of diabetes mellitus (e.g.
  • a drug for the prevention and/or the treatment of restenosis and/or reocclusion such as restenosis and/or reocclusion after percutaneous translummal coronary angioplasty (PTCA) , restenosis and/or reocclusion after the administration of thrombolytic drug (e.g. tissue plas mogen activator (TPA) , etc.) or the like; a drug for the adjuvant therapy with thrombolytic drug (e.g. TPA, etc.) or anticoagulant (e.g. heparin, etc.
  • thrombolytic drug e.g. tissue plas mogen activator (TPA) , etc.
  • TPA tissue plas mogen activator
  • anticoagulant e.g. heparin, etc.
  • DIC disseminated intravascular coagulation
  • thrombotic thrombocytopenia thrombotic thrombocytopenia
  • essential thrombocytosis inflammation
  • inflammation e.g. nephritis, etc.
  • immune diseases e.g. nephritis, etc.
  • the ⁇ -alanine derivative of the present invention is expected to be useful as an inhibitor of cell adhesion and so is expected to be useful as a drug for the prevention and/or the treatment of disseminated intravascular coagulation (DIC) , tnrombotic thrombocytopenia, essential thrombocytosis, inflammation (e.g. nephritis, etc.), immune diseases, or the like; a drug for inhibiting of metastasis; or the like.
  • DIC disseminated intravascular coagulation
  • tnrombotic thrombocytopenia e.g. tnrombotic thrombocytopenia
  • essential thrombocytosis e.g. nephritis, etc.
  • inflammation e.g. nephritis, etc.
  • immune diseases e.g. nephritis, etc.
  • a drug for inhibiting of metastasis e.g. nephritis, etc
  • the object compound (I) can be prepared by the following processes.
  • R 1 is amino protective group
  • Suitable salt of the compounds (II) and (III) are pharmaceutically acceptable salt such as conventional non- toxic salt and include a metal salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.] and an alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.] an ammonium salt, an organic base salt [e.g. tri ethylamine salt, triethylamine salt, pyridine salt, picoline salt dicyclohexylamine salt, N,N- dibenzylethylenediamine salt, etc.], an organic acid addition salt [e.g.
  • a metal salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.] and an alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.] an ammonium salt, an organic base salt [e.g. tri ethylamine salt, triethylamine salt, pyridine salt, picoline salt dicyclohexylamine salt
  • formate acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.]
  • an inorganic acid addition salt e.g. hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, etc.
  • a salt with an amino acid e.g. arginine salt, aspartic acid salt, glutamic acid salt, etc.] and the like.
  • Suitable “lower alkyl” may be straight or branched ones such as methyl, ethyl, isopropyl, propyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, hexyl, isohexyl or the like.
  • Suitable “amino protective group” may include acyl group as explained below, a conventional protecting group such as ar (lower) alkyl which may have 1 to 3 suitable substituent (s) (e.g. benzyl, phenethyl, 1-phenylethyl, benzhydryl, trityl, etc.), [5- (lower) alkyl-2-oxo-l,3- dioxol-4-yl] (lower)alkyl [e.g. (5-methyl-2-oxo-l, 3-dioxol- 4-yl)methyl, etc.] or the like; and the like.
  • suitable substituent e.g. benzyl, phenethyl, 1-phenylethyl, benzhydryl, trityl, etc.
  • [5- (lower) alkyl-2-oxo-l,3- dioxol-4-yl] (lower)alkyl e.g. (5-
  • acyl group and “acyl” may include aliphatic acyl, aromatic acyl, arylaliphatic acyl and heterocyclic-aliphatic acyl derived from carboxylic acid, carbonic acid, carbamic acid, sulfonic acid, and the like.
  • acyl group may be illustrated as follows :
  • aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.); lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbon
  • lower or higher alkylsulfonyl e.g., methylsulfonyl, ethylsulfonyl, etc.
  • lower or higher alkoxysulfonyl e.g., methoxysulfonyl.
  • aromatic acyl such as aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.); ar (lower) alkanoyl [e.g., phenyl (C ⁇ -Cg) alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl (C- ⁇ -Cg) alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.]; ar (lower) alkenoyl [e.g., phenyl (C 3 -Cg) alkenoyl [e.g., phenyl (C 3 -Cg)
  • ar (lower) alkoxycarbonyl e.g., phenyl (C- ⁇ -Cg) - alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.
  • aryloxycarbonyl e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.
  • aryloxy(lower) alkanoyl e.g., phenoxyacetyl, phenoxypropionyl, etc.
  • arylcarbamoyl e.g., phenylcarbamoyl, etc.
  • arylthiocarbamoyl e.g., phenylthiocarbamoyl, etc.
  • arylglyoxyloyl e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.
  • arylsulfonyl which may have 1 to 4 lower alkyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc.); or the like; heterocyclic acyl such as heterocycliccarbonyl; heterocyclic (lower) alkanoyl (e.g., heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc.) ; heterocyclic (lower) alkenoyl (e.g., heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl, heterocyclichexenoyl, etc.); heterocyclicglyoxyloyl; or the like; and the like.
  • heterocyclic acyl such as heterocycliccarbonyl
  • heterocyclic (lower) alkanoyl e.g., heterocyclicacet
  • heterocyclic moiety in the terms “heterocycliccarbonyl”, “heterocyclic (lower) alkyl”, “heterocyclic (lower) alkenoyl” and “heterocyclicglyoxyloyl” as mentioned above, and “heterocyclic group” mean saturated or unsaturated monocyclic or polycyclic heterocyclic group containing at least one hetero-atom such as an oxygen, sulfur, nitrogen atom and the like, in which the preferable heterocyclic group may be heterocyclic group such as unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H
  • the acyl moiety as mentioned above may have one to ten, same or different, suitable substituent (s) such as lower alkyl (e.g., methyl, ethyl, propyl, etc.); lower alkoxy (e.g., methoxy, ethoxy, propoxy, etc.); lower alkylthio (e.g., methylthio, ethylthio, etc.) ; lower alkylamino (e.g., methylamino, ethylamino, propylamino, etc.); cyclo (lower) alkyl [e.g., lower alkyl (e.g., methyl, ethyl, propyl, etc.); lower alkoxy (e.g., methoxy, ethoxy, propoxy, etc.); lower alkylthio (e.g., methylthio, ethylthio, etc.) ; lower alkylamino (e.g.,
  • cyclo (C3-C5) alkyl e.g., cyclopentyl, cyclohexyl, etc.]
  • cyclo (lower) alkenyl e.g. cyclo (C ⁇ C ) alkenyl (e.g., cyclohexenyl, cyclohexadienyl, etc.); halogen (e.g., fluorine, chlorine, bromine, iodine); amino; amino protective group as mentioned above; hydroxy; protected hydroxy as mentioned below; cyano; nitro; carboxy; protected carboxy; sulfo; sulfamoyl; imino; oxo; amino (lower) alkyl (e.g., aminomethyl, aminoethyl, etc.) ; carbamoyloxy; hydroxy (lower) alkyl (e.g., hydroxymethyl, 1 or 2-hydroxyethyl, 1 or 2 or 3-hydroxypropyl, etc.),
  • Suitable "protected hydroxy” may include acyl as mentioned above, phenyl (lower) alkyl which may have one or more suitable substituent (s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), etc.], tetrahydropyranyl and the like.
  • suitable substituent e.g., benzyl, 4-methoxybenzyl, trityl, etc.
  • trisubstituted silyl e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), etc.
  • amino protective group may be lower alkoxycarbonyl or ar (lower) alkoxycarbonyl and the most preferred one may be t-butoxycarbonyl or benzyloxycarbonyl.
  • the object compound (I) can be prepared by subjecting a compound (II) or a salt thereof to elimination reaction of amino protective group. This reaction is . carried out in accordance with a conventional method such as hydrolysis, reduction or the like.
  • the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
  • Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkyla ine [e.g. trimethylamine, triethylamine, etc.], picoline, 1, 5-diazabicyclo[4.3.0]non-5-ene, 1, 4-diazabicyclo[2.2.2]octane, 1, 8-diazabicyclo [5.4.0]undec-7-ene, or the like.
  • Suitable acid may include an organic acid [e.g.
  • the reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g.
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium, sulfate, palladium on barium carbonate, etc.], nickel catalysts [e.g.
  • the reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-d ⁇ methylformam ⁇ de, or a mixture thereof.
  • a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.
  • reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.
  • the object compound (I) can be prepared by subjecting a compound (III) to desalting reaction.
  • This reaction is carried out in accordance with a conventional method such as neutralization, recrystallization, desalting resin column chromatography, or the like.
  • the compounds obtained by the above Processes 1 and 2 can be isolated and purified by a conventional method such as pulverization, recrystallization, colu n- chromatography, reprecipitation, or the like.
  • the object compound (I) may include solvated compound [e.g., enclosure compound (e.g., hydrate, etc.)].
  • solvated compound e.g., enclosure compound (e.g., hydrate, etc.)
  • the object compound (I) is crystalline, and so it is stable and easy to handle.
  • Washed human platelets were prepared from platelet- rich plasma by gel filtration. The washed platelets were activated with 20 ⁇ M ADP for 10 minutes and then fixed for 30 minutes with 0.8% paraformaldehyde. The platelets were then washed by centrifugation and suspended in HEPES- Tyrodes buffer containing 2 mM CaCl 2 and 1 mM MgCl 2 •
  • the pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the object compound (I) , as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.
  • an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.
  • the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments, aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. And, if necessary, in addition, auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.
  • the object compound (I) is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the diseases.
  • the pharmaceutical composition of the present invention can be manufactured by the conventional method in this field of the art. If necessary, the technique generally used in this field of the art for improving the bioavailability of a drug can be applied to the pharmaceutical composition of the present invention.
  • compositions for applying the composition to a human being or an animal, it is preferable to apply it by intravenous (including i.v. infusion), intramuscular, pulmonary, or oral administration, or insufflation including aerosols from metered dose inhalator, nebulizer or dry powder inhalator.
  • While the dosage of therapeutically effective amount of the object compound (I) varies from and also depends upon the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.001-100 mg of the object compound (I) per kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.001-100 mg of the object compound (I) per kg weight of a human being or an animal, in case of oral administration, a daily dose of 0.001-200 mg of the object compound (I) per kg weight of a human being or an animal in generally given for the prevention and/or the treatment of aforesaid diseases in a human being or an animal .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dérivé de β-alanine représenté par la formule (I). Ce dérivé est un antagoniste de la glycoprotéine IIB/IIIa, un inhibiteur de l'agrégation des plaquettes sanguines et un inhibiteur de la liaison du fibrinogène aux plaquettes sanguines. L'invention porte également sur des procédés d'élaboration de ce dérivé, sur une composition pharmaceutique le renfermant et sur une méthode de prévention et/ou de traitement de maladies indiquées dans la description de l'invention, chez l'être humain et l'animal.
EP97907277A 1996-03-13 1997-03-12 N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene Withdrawn EP0888302A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA962033A ZA962033B (en) 1995-03-17 1996-03-13 New compound
ZA9602033 1996-03-13
PCT/JP1997/000769 WO1997033869A1 (fr) 1996-03-13 1997-03-12 N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene

Publications (1)

Publication Number Publication Date
EP0888302A1 true EP0888302A1 (fr) 1999-01-07

Family

ID=65952245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97907277A Withdrawn EP0888302A1 (fr) 1996-03-13 1997-03-12 N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene

Country Status (5)

Country Link
EP (1) EP0888302A1 (fr)
JP (1) JP2000506524A (fr)
KR (1) KR19990087694A (fr)
CA (1) CA2248809A1 (fr)
WO (1) WO1997033869A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
AUPP646598A0 (en) * 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
AU769718B2 (en) * 1998-10-12 2004-02-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing beta-alanine derivative
BR0010652A (pt) * 1999-03-22 2002-07-16 Ortho Mcneil Pharm Inc Processo de preparação de ácido [s-(r*,s*)]-beta-[[[1-[1-oxo-3-(4-piperidinil)propil]-3-piperi dinil]carbonil]amino]-3-piridinapropanóico e derivados
JP2001131078A (ja) * 1999-11-09 2001-05-15 Iatron Lab Inc 新規活性固定化血小板及びその製造方法
AUPQ570100A0 (en) 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
WO2005079863A1 (fr) * 2004-02-25 2005-09-01 Astellas Pharma Inc. Produit de contraste pour la formation d'un thrombus
US9345793B2 (en) 2011-08-17 2016-05-24 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi
CN105189521A (zh) 2013-02-12 2015-12-23 拜耳医药股份公司 结合至血小板特异性糖蛋白IIb/IIIa的金属螯合化合物
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2037153A1 (fr) * 1990-03-09 1991-09-10 Leo Alig Derives de l'acide acetique
WO1992019595A1 (fr) * 1991-05-07 1992-11-12 Merck & Co., Inc. Antagonistes de recepteur de fibrinogene
CA2157792C (fr) * 1993-09-22 2005-05-24 Mitsuru Ohkubo Derives de n-(3-piperidinylcarbonyl)-beta-alanine, antagonistes du paf
DE69426602T2 (de) * 1993-10-19 2001-08-30 Sumitomo Pharmaceuticals Co., Ltd. 2,3-diaminopropionsäurederivate
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
KR19980703107A (ko) * 1995-03-17 1998-10-15 후지야마 아키라 N-아실피페리디닐카보닐아미노카복실산 및 당단백질 IIB/IIa 길항제와 피브리노겐-혈소판 결합 억제제로서의 이의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9733869A1 *

Also Published As

Publication number Publication date
CA2248809A1 (fr) 1997-09-18
WO1997033869A1 (fr) 1997-09-18
JP2000506524A (ja) 2000-05-30
KR19990087694A (ko) 1999-12-27

Similar Documents

Publication Publication Date Title
US20050192208A2 (en) Ion channel modulating compounds and uses thereof
EP1870405A1 (fr) (Aza)cyclohexanes carbonylées comme ligands du récepteur D3 de la dopamine
KR910007968B1 (ko) 축합 7원 고리 화합물의 제조방법
CA2320378A1 (fr) Dipeptides cycliques et composes d'azetidinone et leur utilisation afin de traiter des lesions du systeme nerveux central et des maladies neurodegeneratives
US6432985B2 (en) Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
EP0888302A1 (fr) N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene
DE69429328T2 (de) N-(3-piperidinylcarbonyl)-b-alanin derivate als paf-antagonisten
AU2016245418B2 (en) Novel pyridinium compounds
US6384028B1 (en) N-acylpiperidinylcarbonylaminocarboxylic acids and their use as glycoprotein IIb/IIIa antagonists and fibrinogen-blood platelets binding inhibitors
EP1124824B1 (fr) Derives de chromenone et de chromanone utilises comme inhibiteurs d'integrine
US20010016571A1 (en) N-[ (R) -1-{3- (4- piperidyl) propionyl } -3-piperidylcarbonyl] -2 (S) -acetylamino-beta -alanine as fibrinogen receptor antagonist
KR20110017452A (ko) 무스칼린 수용체 길항제로서 활성인 신규한 화합물
CA2268590A1 (fr) Composes de regulation des canaux ioniques et utilisations de ces produits
CA2012901A1 (fr) Derives d'acides amines
EP1483285B1 (fr) INHIBITEURS DU FACTEUR DE COAGULATION Xa, LEUR PRODUCTION ET LEUR UTILISATION
US6538007B1 (en) N-[(R)-1-[3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-2(S)-acetylamino-β-alanine trihydrate, compositions thereof, and methods for its use
WO2001096365A1 (fr) Pyridin-2-yl-aminoalkylcarbonylglycyl-$g(b)-alanine et ses derives
OA12180A (en) Cyclic hexapeptide derivatives.
US5952299A (en) Cyclic peptide nuclei and derivatives thereof
DE19653036A1 (de) Cyclopeptidderivate
KR100295353B1 (ko) 베타-알라닌유도체및이의제조방법
WO2023133457A1 (fr) Nouveaux inhibiteurs de kalirine pour la régulation de la plasticité synaptique et le traitement de la douleur neuropathique
RU1063059C (ru) Гидрохлориды производных 2-карбэтокси-4-оксибензофурана, обладающие противоаритмической и противофибрилл торной активностью
JP2000229998A (ja) 新規化合物
JPH08283260A (ja) ピリダジノン誘導体及びその製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980814

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020702

RTI1 Title (correction)

Free format text: N- (R)-1- 3-(4-PIPERIDYL)PROPIONYL-3-PIPERIDYLCARBONYL -2(S)-ACETYLAMINO-BETA-ALANINE AS FIBRINOGEN RECEPTOR ANTAGONIST